Lannett Company Inc (LCI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
52
About the Report
About the Report
Summary
Lannett Company Inc (Lannett) is a pharmaceutical company. It develops, manufactures and distributes generic prescription pharmaceutical products in tablet, capsule and oral liquid forms. The company offers generic pharmaceuticals for medical indications such as antibiotic, cardiovascular, central nervous systems, gallstone, gastrointestinal, glaucoma, gout, migraine, muscle relaxant, obesity, pain management, respiratory, thyroid deficiency and urinary. Lannett also offers laboratory services, product formulation and development services, granulation, blending, encapsulation, compression, coating and packaging solid dosage forms. The company sells its pharmaceutical products across the US to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private-label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations and health maintenance organizations. Lannett is headquartered in Philadelphia, Pennsylvania, the US.
Lannett Company Inc (LCI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Lannett Company Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lannett Company Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Lannett Company Inc, Medical Devices Deals, 2012 to YTD 2018 11
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Lannett Company Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Lannett Acquires Portfolio of Generic Products from Endo International 13
Lannett to Acquire Estradiol Tablets and Selegiline Hydrochloride Capsules 14
Partnerships 15
Lannett Enters into Distribution Agreement with Aralez Pharma 15
Lannett to Form Partnership with YiChang HEC ChangJiang Pharmaceutical 16
Lannett Enters into Co-Marketing Agreement with Sunshine Lake 17
Panacea Biotec Enters Into R&D Agreement With Kremers Urban For Generic Drugs 18
Licensing Agreements 19
Lannett Amends Licensing Agreement with Andor Pharma 19
Equity Offering 20
Lannett Company Files Registration Statement to Raise Funds through Public Offering of Securities 20
Lannett Completes Public Offering Of Shares For USD 76.5 Million 21
Lannett Files Shelf Registration Statement For Public Offering Of Securities For Up To USD 64 Million 22
Acquisition 23
Lannett Company Plans to Sell Cody Laboratories 23
Lannett Acquires Kremers Urban Pharma for USD1.23 Billion 24
Lannett Acquires Silarx Pharma for USD42 Million 26
Lannett Company Inc-Key Competitors 27
Lannett Company Inc-Key Employees 28
Lannett Company Inc-Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Aug 20, 2018: Lannett announces preliminary fiscal 2018 fourth-quarter and full-year financial results 30
May 07, 2018: Lannett Announces Fiscal 2018 Third-Quarter Financial Results 31
Feb 07, 2018: Lannett Announces Fiscal 2018 Second-Quarter Financial Results; Reports Record Revenues, Strong Earnings 32
Nov 06, 2017: Lannett Reports Solid Fiscal 2018 First-Quarter Financial Results, Significantly Increases Fiscal 2018 Guidance 33
Aug 23, 2017: Lannett Reports Fiscal 2017 Fourth-Quarter And Full-Year Financial Results, Provides Guidance For Fiscal 2018 34
Aug 08, 2017: Lannett Announces Preliminary Fiscal 2017 Fourth-Quarter And Full-Year Financial Results, Comments On Fiscal 2018 Outlook 35
May 02, 2017: Lannett Reports Fiscal 2017 Third-Quarter Financial Results 36
Feb 01, 2017: Lannett Reports Fiscal 2017 Second-Quarter Financial Results 37
Corporate Communications 38
Apr 30, 2018: Lannett Announces Changes To Board Of Directors 38
Apr 20, 2018: Lannett Names Maureen Cavanaugh Senior Vice President And Chief Commercial Operations Officer 39
Jan 18, 2018: Lannett Appoints Timothy C. Crew As Board Of Directors 40
Dec 21, 2017: Lannett Appoints Timothy C. Crew As CEO 41
Sep 25, 2017: Lannetts Board Of Directors Initiates CEO Search 42
Jul 17, 2017: Lannett Appoints Samuel H. Israel As General Counsel 43
Jun 20, 2017: Lannett Names Patrick G. LePore To Board of Directors 44
Legal and Regulatory 45
Nov 01, 2017: Lannett Comments On Amended Civil Complaint 45
Product News 46
Jul 23, 2018: Lannett Announces Multiple Product Launches 46
06/26/2017: Lannett Receives Approval For Additional Dosage Strengths Of Hydrocodone Bitartrate And Acetaminophen Tablets USP 47
Other Significant Developments 48
Jun 29, 2018: Lannett Announces Restructuring Plan Of Cody Laboratories Subsidiary 48
Mar 12, 2018: Lannett Adds New Revenue Streams, Announces Agreements With Three Strategic Alliance Partners 49
Mar 30, 2017: Lannett Voluntarily Pays Down Additional USD 25 Million Of Revolving Credit Facility 50
Feb 07, 2017: Lannett Announces Successful Completion Of ERP System Extraction 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52
List of Figure
List of Figures
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Lannett Company Inc, Medical Devices Deals, 2012 to YTD 2018 11
List of Table
List of Tables
Lannett Company Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lannett Company Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lannett Company Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Lannett Company Inc, Medical Devices Deals, 2012 to YTD 2018 11
Lannett Company Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Lannett Acquires Portfolio of Generic Products from Endo International 13
Lannett to Acquire Estradiol Tablets and Selegiline Hydrochloride Capsules 14
Lannett Enters into Distribution Agreement with Aralez Pharma 15
Lannett to Form Partnership with YiChang HEC ChangJiang Pharmaceutical 16
Lannett Enters into Co-Marketing Agreement with Sunshine Lake 17
Panacea Biotec Enters Into R&D Agreement With Kremers Urban For Generic Drugs 18
Lannett Amends Licensing Agreement with Andor Pharma 19
Lannett Company Files Registration Statement to Raise Funds through Public Offering of Securities 20
Lannett Completes Public Offering Of Shares For USD 76.5 Million 21
Lannett Files Shelf Registration Statement For Public Offering Of Securities For Up To USD 64 Million 22
Lannett Company Plans to Sell Cody Laboratories 23
Lannett Acquires Kremers Urban Pharma for USD1.23 Billion 24
Lannett Acquires Silarx Pharma for USD42 Million 26
Lannett Company Inc, Key Competitors 27
Lannett Company Inc, Key Employees 28
Lannett Company Inc, Other Locations 29
Lannett Company Inc, Subsidiaries 29
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.